[go: up one dir, main page]

CU24743B1 - Composiciones inmunogénicas contra el coronavirus - Google Patents

Composiciones inmunogénicas contra el coronavirus

Info

Publication number
CU24743B1
CU24743B1 CU2022000050A CU20220050A CU24743B1 CU 24743 B1 CU24743 B1 CU 24743B1 CU 2022000050 A CU2022000050 A CU 2022000050A CU 20220050 A CU20220050 A CU 20220050A CU 24743 B1 CU24743 B1 CU 24743B1
Authority
CU
Cuba
Prior art keywords
immunogenetic
compositions against
against coronavirus
coronavirus
cov
Prior art date
Application number
CU2022000050A
Other languages
English (en)
Other versions
CU20220050A7 (es
Inventor
Kate Broderick
Kar Muthumani
Ami Patel
David Weiner
Jian Yan
Original Assignee
Inovio Pharmaceuticals Inc
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inovio Pharmaceuticals Inc, Wistar Inst filed Critical Inovio Pharmaceuticals Inc
Publication of CU20220050A7 publication Critical patent/CU20220050A7/es
Publication of CU24743B1 publication Critical patent/CU24743B1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/215Coronaviridae, e.g. avian infectious bronchitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20041Use of virus, viral particle or viral elements as a vector
    • C12N2770/20044Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>La presente invención está relacionada con las moléculas de ácido nucleico que codifican un antígeno<br /> de pico del coronavirus 2 del síndrome respiratorio agudo severo (SARS-CoV-2), vector de expresión y composiciones inmunogénicas que los comprende.</p>
CU2022000050A 2020-02-25 2021-02-25 Composiciones inmunogénicas contra el coronavirus CU24743B1 (es)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202062981168P 2020-02-25 2020-02-25
US202062981451P 2020-02-25 2020-02-25
US202063004380P 2020-04-02 2020-04-02
US202063022032P 2020-05-08 2020-05-08
US202063028404P 2020-05-21 2020-05-21
US202063033349P 2020-06-02 2020-06-02
US202063040865P 2020-06-18 2020-06-18
US202063046415P 2020-06-30 2020-06-30
US202063056996P 2020-07-27 2020-07-27
US202063063157P 2020-08-07 2020-08-07
US202063062762P 2020-08-07 2020-08-07
US202063114858P 2020-11-17 2020-11-17
US202063130593P 2020-12-24 2020-12-24
US202163136973P 2021-01-13 2021-01-13
PCT/US2021/019662 WO2021173829A1 (en) 2020-02-25 2021-02-25 Vaccines against coronavirus and methods of use

Publications (2)

Publication Number Publication Date
CU20220050A7 CU20220050A7 (es) 2023-04-10
CU24743B1 true CU24743B1 (es) 2025-03-10

Family

ID=75108858

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2022000050A CU24743B1 (es) 2020-02-25 2021-02-25 Composiciones inmunogénicas contra el coronavirus

Country Status (16)

Country Link
US (3) US11660335B2 (es)
EP (1) EP4110468A1 (es)
JP (2) JP2023511780A (es)
KR (1) KR20220157969A (es)
CN (1) CN115867349A (es)
AU (2) AU2021226567B2 (es)
BR (1) BR112022016507A2 (es)
CA (1) CA3168353A1 (es)
CO (1) CO2022012272A2 (es)
CU (1) CU24743B1 (es)
IL (1) IL295697B1 (es)
MX (1) MX2022010460A (es)
NZ (1) NZ791834A (es)
PE (1) PE20230171A1 (es)
PH (1) PH12022552249A1 (es)
WO (1) WO2021173829A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230210981A1 (en) * 2020-06-09 2023-07-06 The Wistar Institute Of Anatomy And Biology Coronavirus disease 2019 (covid-19) combination vaccine
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
US20220370598A1 (en) * 2021-05-05 2022-11-24 Inovio Pharmaceuticals, Inc. Vaccines Against Coronavirus and Methods of Use
WO2023035016A1 (en) * 2021-09-03 2023-03-09 The Uab Research Foundation Human neutralizing antibodies against sars-cov-2 spike s2 domain and uses thereof
WO2023073672A1 (en) * 2021-10-29 2023-05-04 Geneone Life Science, Inc. Therapeutic and vaccine candidates against sars-cov-2
CN116410272A (zh) * 2023-03-06 2023-07-11 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) 一种新型冠状病毒s蛋白特异性b细胞抗原表位多肽及其应用
AU2024270076A1 (en) * 2023-05-10 2025-11-27 Seqirus Inc. Combination vaccine

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US3805783A (en) 1971-02-12 1974-04-23 A Ismach Hand powered hypodermic jet injector gun
US4342310A (en) 1980-07-08 1982-08-03 Istvan Lindmayer Hydro-pneumatic jet injector
US4447223A (en) 1982-04-16 1984-05-08 Cct Associates Medicament implant applicator
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5843463A (en) 1990-12-21 1998-12-01 Antexbiologics, Inc. Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
WO1993025673A1 (en) 1992-06-04 1993-12-23 The Regents Of The University Of California In vivo gene therapy with intron-free sequence of interest
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5505697A (en) 1994-01-14 1996-04-09 Mckinnon, Jr.; Charles N. Electrically powered jet injector
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6009347A (en) 1998-01-27 1999-12-28 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
EP1102608A4 (en) 1998-07-13 2008-09-17 Genetronics Inc METHOD AND APPARATUS FOR THE ELECTRICALLY SUPPORTED SURFACE APPLICATION OF COSMETIC MEANS
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
AU4996300A (en) 1999-05-10 2000-11-21 Gentronics, Inc. Method of electroporation-enhanced delivery of active agents
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US20050025788A1 (en) * 2003-06-06 2005-02-03 Chou George Chin-Sheng Systemic delivery of non-viral vector expressing SARS viral genomic vaccine
KR20160091350A (ko) 2013-11-29 2016-08-02 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
TW202204380A (zh) 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法-sars-cov-2疫苗
US10906944B2 (en) 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines

Also Published As

Publication number Publication date
BR112022016507A2 (pt) 2022-11-22
US20230338515A1 (en) 2023-10-26
IL295697A (en) 2022-10-01
US11660335B2 (en) 2023-05-30
EP4110468A1 (en) 2023-01-04
AU2021226567B2 (en) 2025-04-17
PE20230171A1 (es) 2023-02-01
JP2025010171A (ja) 2025-01-20
AU2021226567A1 (en) 2022-10-13
KR20220157969A (ko) 2022-11-29
US20250121054A1 (en) 2025-04-17
JP2023511780A (ja) 2023-03-22
WO2021173829A1 (en) 2021-09-02
IL295697B1 (en) 2026-02-01
US20210268102A1 (en) 2021-09-02
CN115867349A (zh) 2023-03-28
CO2022012272A2 (es) 2022-11-29
AU2025205555A1 (en) 2025-08-07
PH12022552249A1 (en) 2023-11-13
MX2022010460A (es) 2022-09-19
CA3168353A1 (en) 2021-09-02
NZ791834A (en) 2026-01-30
CU20220050A7 (es) 2023-04-10

Similar Documents

Publication Publication Date Title
CU24743B1 (es) Composiciones inmunogénicas contra el coronavirus
MX386123B (es) Productos de champú compactos y estables con baja viscosidad y agente reductor de viscosidad.
MX2022005380A (es) Composiciones que comprenden colina.
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
MX2020002191A (es) Agentes antivirales contra la hepatitis b.
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
BR112022026414A2 (pt) Métodos para detectar sars-cov-2, influenza e rsv
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
MX2020001885A (es) Formulaciones de daptomicina.
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
CL2018003814A1 (es) Método para el cuidado de la piel.
MX2021014680A (es) Derivado de benzotriazol.
AR105010A1 (es) Composiciones inmunógenas
MX2023014437A (es) Compuestos de triptamina fluorada, análogos de estos y métodos de uso estos.
CO2023000239A2 (es) Excipientes reductores de viscosidad y combinaciones de los mismos para formulaciones de proteína altamente concentradas
ECSP22040921A (es) Composición farmacéutica que comprende selexipag
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato
MX2017015812A (es) Formulaciones farmaceuticas inyectables de lefamulina.
NO20060242L (no) Kombinasjonen av en serotonin-reopptaksinhibitor og agomelatin
CL2024000248A1 (es) Composiciones y métodos para anticuerpos anti-pacap
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
EA202090971A1 (ru) Способы применения и композиции, содержащие дулаглутид
BR112023022917A2 (pt) Moduladores de trex1
BR112022023135A2 (pt) Amidas tricíclicas substituídas, análogos das mesmas e métodos que usam as mesmas
BRPI0516542A (pt) composição de vacina eficaz na prevenção ou melhora de infecção pelo vìrus da influenza aviária; método para prevenir ou melhorar a eclosão de infecção pelo vìrus da influenza aviária